Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript

Akums Drugs and Pharmaceuticals reported Q1FY26 total income of Rs. 1,051 crores, up 2.4% year-on-year, with reported EBITDA of Rs. 156 crores (+19% YoY) and margins expanding 208 basis points to 14.8%. The CDMO segment, 77% of revenue, grew 4% YoY to Rs. 813 crores despite a 2.5% drag from falling API prices, with EBITDA margins steady at 14.7%. Management trimmed full-year CDMO growth guidance from mid-to-high single digits to mid-single digits. Domestic branded formulation grew 3.4% to Rs. 107 crores with full-year margin guided around 18%. The company holds Rs. 1,518 crores in cash after receiving €100 million as part payment for its European CDMO contract (Rs. 300+ crores annual revenue from April 2027). It targets $100 million in total formulation exports over five years, with plans to own 10 dossiers in Europe. API losses were cut 50% YoY, while the trade generic segment continues to be rationalized.